Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1.

Neutropenia complicates HIV disease or its treatment in a large proportion of patients. Hematopoietic growth factor support has been tested in a number of clinical settings in HIV disease and has been demonstrated to be of benefit for specific parameters. One consideration regarding the use of hematopoietic growth factors in HIV disease is their potential effect on HIV viral burden, since alterations in HIV expression have been documented with certain cytokines in vitro. It has also been reported that some cytokines, notably GM-CSF, potentiate the antiviral properties of thymidine analogs such as zidovudine (AZT) in vitro. We tested these observations in vivo. Twelve HIV-positive patients with a CD4 cell count < or = 200/mm3 or HIV plasma viremia who were receiving a stable dose of zidovudine were enrolled into three dose cohorts of yeast-derived GM-CSF at 50, 125, or 250 micrograms/m2 daily by subcutaneous self-injection for 28 days. Measurements of HIV activity included serum acid-dissociated HIV p24 antigen levels, plasma and peripheral blood mononuclear cell (PBMC) limiting dilution HIV culture, and plasma HIV quantitative competitive polymerase chain reaction (PCR). Serum and intracellular zidovudine levels were measured as well as hematologic, immunologic, and toxicity parameters. Virologic measures showed neither significant upregulation nor downregulation of serum acid-dissociated HIV p24 antigen, plasma and PBMC HIV culture, or PCR in association with GM-CSF administration. A trend toward increased intracellular AZT levels was noted, but this did not achieve statistical significance (p = 0.073). CD4 and CD8 lymphocytes were essentially unaffected while absolute neutrophil counts increased with GM-CSF administration as expected. These data suggest that administration of GM-CSF does not perturb HIV activity or immunologic parameters in patients receiving AZT for advanced HIV disease. No potentiation of AZT antiviral effect was demonstrated.

[1]  S. Hammer,et al.  In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. , 1995, AIDS research and human retroviruses.

[2]  M. Vitale,et al.  A subset of human CD34+ hematopoietic progenitors express low levels of CD4, the high-affinity receptor for human immunodeficiency virus-type 1. , 1994, Blood.

[3]  G. Mufti,et al.  Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant human granulocyte macrophage colony stimulating factor. , 1994, Journal of clinical pathology.

[4]  E. Brummer,et al.  Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans , 1994, Antimicrobial Agents and Chemotherapy.

[5]  A. Pesce,et al.  Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity , 1994, AIDS.

[6]  L. Bermudez,et al.  Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. , 1994, The Journal of infectious diseases.

[7]  J. Curtis,et al.  Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. , 1994, Journal of immunology.

[8]  R. Calderone,et al.  Macrophage interactions with Candida. , 1994, Immunology series.

[9]  N. Obel,et al.  Phagocytosis and stimulation of the respiratory burst in neutrophils by Pneumocystis carinii. , 1993, The Journal of infectious diseases.

[10]  R. Appelberg,et al.  Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages. , 1993, Immunology.

[11]  J. Bartolomé,et al.  Pilot study of recombinant human granulocyte‐macrophage colony–stimulating factor in the treatment of chronic hepatitis B , 1993, Hepatology.

[12]  R. Badaró,et al.  Local peri-lesional therapy with rhGM-CSF for Kaposi's sarcoma , 1993, The Lancet.

[13]  M. Goldberg,et al.  HIV-1 suppresses erythropoietin production in vitro. , 1993, Experimental hematology.

[14]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[15]  B. Poiesz,et al.  Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex , 1993, Antimicrobial Agents and Chemotherapy.

[16]  M. Richardson,et al.  Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. , 1992, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[17]  A. Sampson,et al.  Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials , 1992 .

[18]  A. Lazzarin,et al.  Membrane Expression and Function of Complement Receptors CR1 and CR3 on Neutrophils from HIV‐Infected Subjects: Modulation by rTNF‐α and rGM‐CSF , 1992, Scandinavian journal of immunology.

[19]  E. R. Stiehm,et al.  Deficient polymorphonuclear cell and mononuclear cell antibody-dependent cellular cytotoxicity in pediatric and adult human immunodeficiency virus infection. , 1992, The Journal of infectious diseases.

[20]  A. Foli,et al.  Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages , 1992 .

[21]  N. Flomenberg,et al.  Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Scadden,et al.  Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction. , 1992, The Journal of infectious diseases.

[23]  G. Bancroft,et al.  Cytokine enhancement of complement‐dependent phagocytosis by macrophages: synergy of tumor necrosis factor‐α and granulocyte‐macrophage colony‐stimulating factor for phagocytosis of Cryptococcus neoformans , 1992, European journal of immunology.

[24]  D. Golde,et al.  Activation of human eosinophil and neutrophil functions by haematopoietic growth factors: comparisons of IL‐1, IL‐3, IL‐5 and GM‐CSF , 1992, British journal of haematology.

[25]  J. Groopman,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. , 1991, Blood.

[26]  M. B. Taylor,et al.  The neutrophil chemiluminescence response to Pneumocystis carinii is stimulated by GM-CSF and gamma interferon. , 1991, FEMS microbiology immunology.

[27]  A. Athamna,et al.  Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. , 1991, Lymphokine and cytokine research.

[28]  J. Metcalf,et al.  A Phase I/II Trial of Zidovudine, Interferon-α, and Granulocyte-Macrophage Colony-Stimulating Factor in the Treatment of Human Immunodeficiency Virus Type 1 Infection , 1991 .

[29]  D. Blanchard,et al.  Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M. intracellulare: activation of bactericidal activity by GM-CSF , 1991, Infection and immunity.

[30]  J. Kahn,et al.  Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Baldwin,et al.  Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. , 1991, Blood.

[32]  D. Scadden,et al.  Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Merigan,et al.  Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo , 1991, Journal of virology.

[34]  C. Crumpacker,et al.  In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus , 1991, Journal of virology.

[35]  D. Kufe,et al.  Effects of granulocyte-macrophage colony-stimulating factor on 3'-azido-3'-deoxythymidine uptake, phosphorylation and nucleotide retention in human U-937 cells. , 1990, Biochemical pharmacology.

[36]  D. Scadden,et al.  Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. , 1990, Blood.

[37]  T. Walsh,et al.  Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. , 1990, The Journal of pediatrics.

[38]  M. Dietrich,et al.  CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. , 1990, Blood.

[39]  J. Djeu Role of tumor necrosis factor and colony-stimulating factors in phagocyte function against Candida albicans. , 1990, Diagnostic microbiology and infectious disease.

[40]  S. Broder,et al.  Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. , 1990, Blood.

[41]  L. Bermudez,et al.  Recombinant Granulocyte–Macrophage Colony‐Stimulating Factor Activates Human Macrophages to Inhibit Growth or Kill Mycobacterium avium Complex , 1990, Journal of leukocyte biology.

[42]  S. Banks,et al.  Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. , 1990, The Journal of infectious diseases.

[43]  S. Hammer,et al.  Effect of zidovudine and granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus replication in alveolar macrophages. , 1990, Blood.

[44]  N. Yamamoto,et al.  Effect of interleukin-1 on the augmentation of human immunodeficiency virus gene expression. , 1989, Biochemical and biophysical research communications.

[45]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[46]  D. Scadden,et al.  Pathophysiology and management of HIV-associated hematologic disorders. , 1989, Blood.

[47]  G. Baldwin,et al.  Granulocyte- and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells. , 1989, Blood.

[48]  G. Nabel,et al.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. S. Webb,et al.  Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido- 2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine , 1989, The Journal of experimental medicine.

[50]  E. Jaffe,et al.  Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow , 1988, Science.

[51]  W. O'brien,et al.  Cytokines alter production of HIV-1 from primary mononuclear phagocytes. , 1988, Science.

[52]  D. Golde,et al.  Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Justement,et al.  Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. , 1987, Science.

[54]  M. Greenberg,et al.  A glycoprotein inhibitor of in vitro granulopoiesis associated with AIDS. , 1987, Blood.

[55]  J. Groopman,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. , 1987, The New England journal of medicine.

[56]  A. Ganser,et al.  Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome. , 1987, The Journal of clinical investigation.

[57]  S. Hammer,et al.  Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[58]  J. Groopman,et al.  Suppression of in vitro haematopoiesis following human immunodeficiency virus infection , 1987, Nature.

[59]  S. Hammer,et al.  In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[60]  T. Quinn,et al.  Hematologic abnormalities in the acquired immune deficiency syndrome. , 1984, The American journal of medicine.

[61]  P. Volberding,et al.  Hematologic manifestations in homosexual men with Kaposi's sarcoma. , 1984, American journal of clinical pathology.